Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adulterated supplements

This article was originally published in The Tan Sheet

Executive Summary

Rx ingredients warfarin (blood thinner) and alprazolam (anxiety/panic disorder treatment) found by California Department of Health Services in dietary supplements PC SPES and SPES, respectively, department says Feb. 7. Brea, Calif.-based BotanicLab is recalling both products. PC SPES is sold in 60-count bottles, SPES in 30-count bottles; both are marketed for "prostate health." No adverse events have been reported to date...

You may also be interested in...



AACR Annual Meeting In Brief

Shanghai Breast Cancer Study: Green tea consumption associated with 15% decreased breast cancer risk, Martha Shrubsole, Vanderbilt University and Shanghai Cancer Institute, et al., report at American Association of Cancer Research annual meeting in San Francisco, Calif. April 6-10. Risk further declined with increased years of green tea consumption, number of servings/day. Multivitamin intake led to 48% reduced risk, with 30%, 25%, 27% decreases in breast cancer risk associated with vitamin B, C, E consumption, respectively; no duration or dose-response correlations were detected. Ginseng use did not ameliorate breast cancer risk. Study involved in-person interviews with 1,459 cases and 1,556 controls...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093589

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel